Distinguished in Oligodendroglioma

Dr. Stuart Grossman

Oncology
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Offers Telehealth

Distinguished in Oligodendroglioma
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester.

Dr. Grossman is rated as a Distinguished provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 1 clinical trial in the study of Oligodendroglioma.

Residency
University of Rochester Medical Center, Internal Medicine, 1976
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Medical Oncology, 1981
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: EGFR(V)-EDV-Dox
Study Phase: Phase 1
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP Inhibitor, Temozolomide
Study Phase: Phase 1/Phase 2
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug, Radiation
Study Drugs: Adavosertib, Temozolomide
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Enrollment Status: Terminated
Publish Date: April 04, 2024
Intervention Type: Other, Drug, Procedure
Study Drug: Sapanisertib
Study Phase: Phase 1
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme
A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban
Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban
Enrollment Status: Terminated
Publish Date: December 02, 2022
Intervention Type: Other
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
View 13 Less Clinical Trials

149 Total Publications

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.
Journal: Neuro-oncology advances
Published: July 24, 2025
View All 149 Publications
Similar Doctors
Matthias Holdhoff
Elite in Oligodendroglioma
Dr. Matthias Holdhoff
Oncology
Elite in Oligodendroglioma
Dr. Matthias Holdhoff
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Solmaz Sahebjam
Distinguished in Oligodendroglioma
Dr. Solmaz Sahebjam
Oncology
Distinguished in Oligodendroglioma
Dr. Solmaz Sahebjam
Oncology

Sibley Memorial Hospital

Washington, DC 
 (37.2 miles away)
202-660-6500
Languages Spoken:
English, Azerbaijani, Farsi, French
See accepted insurances
Offers Telehealth

Dr. Solmaz Sahebjam is a medical oncologist and an associate professor of oncology at Johns Hopkins University School of Medicine. Her expertise is in primary and metastatic brain tumors, breast cancer, and the development of new drugs for cancer. She earned her medical degree from Iran University of Medical Sciences, followed by a post-doctoral research fellowship at Shriners Hospital, McGill University in Montreal. Dr. Sahebjam completed residency training in internal medicine at Saint Vincent Hospital, followed by a fellowship in internal medicine at the University of Ottawa in Canada. She continued her training with a residency in medical oncology at McGill University in Canada followed by a fellowship in early-phase drug development, breast oncology, and neurooncology at Princess Margaret Hospital, University of Toronto in Canada. Dr. Sahebjam’s research is focused on the development of novel therapeutic regimens for the treatment of cancer including breast and central nervous system malignancies. Over the years, she has led and contributed to numerous clinical trials some of which have resulted in new treatment options for patients with cancer. Dr. Sahebjam is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Glioma, Brain Tumor, Glioblastoma, Astrocytoma, and Awake Craniotomy.

Distinguished in Oligodendroglioma
Dr. Adam L. Cohen
Oncology
Distinguished in Oligodendroglioma
Dr. Adam L. Cohen
Oncology

Inova Health Care Services

8081 Innovation Park Dr, 
Fairfax, VA 
 (45.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Cohen is an Oncologist in Fairfax, Virginia. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, Bone Marrow Aspiration, and Liver Embolization. Dr. Cohen is currently accepting new patients.

VIEW MORE OLIGODENDROGLIOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grossman's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Grossman is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Grossman is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioblastoma
    Dr. Grossman is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Grossman is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Gliomatosis Cerebri
    Dr. Grossman is
    Elite
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Grossman is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Grossman is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Grossman is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Neuroepithelioma
    Dr. Grossman is
    Distinguished
    . Learn about Neuroepithelioma.
    See more Neuroepithelioma experts
  • Oligodendroglioma
    Dr. Grossman is
    Distinguished
    . Learn about Oligodendroglioma.
    See more Oligodendroglioma experts
  • Pediatric Low-Grade Glioma (pLGG)
    Dr. Grossman is
    Distinguished
    . Learn about Pediatric Low-Grade Glioma (pLGG).
    See more Pediatric Low-Grade Glioma (pLGG) experts
View All 8 Distinguished Conditions
  • Advanced
  • Brain Stem Cancer
    Dr. Grossman is
    Advanced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Grossman is
    Advanced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Metastatic Brain Tumor
    Dr. Grossman is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Experienced
  • Agranulocytosis
    Dr. Grossman is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Breast Cancer
    Dr. Grossman is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Lung Cancer
    Dr. Grossman is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Melanoma
    Dr. Grossman is
    Experienced
    . Learn about Melanoma.
    See more Melanoma experts
  • Non-Hodgkin Lymphoma
    Dr. Grossman is
    Experienced
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Grossman is
    Experienced
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.